Almirall Seeks EMA Approval to Expand Ebglyss Use in Kids
BARCELONA, Spain, July 17, 2026 Almirall S.A. has announced that the European Medicines Agency (EMA) has accepted the Marketing...
clinical oncology
Advertisement
Marengo Earns ESMO Oral Slot for Phase II Cancer Data
CAMBRIDGE, Mass., July 20, 2026 Marengo Therapeutics has announced that updated Phase II clinical data from its investigational immunotherapy...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Advertisements
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Menarini Group Reports Promising Elacestrant-Capivasertib Results in Metastatic Breast Cancer at ASCO 2026
FLORENCE, Italy and NEW YORK, May 28, 2026 Menarini Group and its wholly owned subsidiary Stemline Therapeutics have announced...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Advertisement
